Tudor Investment Corp ET AL Sells 370,036 Shares of Guardant Health, Inc. (NASDAQ:GH)

Tudor Investment Corp ET AL trimmed its stake in Guardant Health, Inc. (NASDAQ:GH) by 93.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,839 shares of the company’s stock after selling 370,036 shares during the period. Tudor Investment Corp ET AL’s holdings in Guardant Health were worth $850,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in GH. R Squared Ltd acquired a new position in shares of Guardant Health during the fourth quarter worth $26,000. SBI Securities Co. Ltd. purchased a new stake in Guardant Health in the fourth quarter valued at about $43,000. Kimelman & Baird LLC acquired a new stake in Guardant Health in the fourth quarter worth about $58,000. NewEdge Advisors LLC grew its stake in shares of Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after acquiring an additional 230 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Guardant Health during the fourth quarter valued at about $80,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Stock Performance

GH opened at $41.98 on Wednesday. The company has a fifty day moving average of $43.76 and a two-hundred day moving average of $38.54. The stock has a market capitalization of $5.20 billion, a price-to-earnings ratio of -11.79 and a beta of 1.49. Guardant Health, Inc. has a fifty-two week low of $18.01 and a fifty-two week high of $52.92.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. The firm had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Guardant Health’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.46) EPS. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on GH shares. TD Securities lifted their target price on shares of Guardant Health from $56.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, May 1st. Mizuho began coverage on shares of Guardant Health in a research note on Thursday, April 10th. They set an “outperform” rating and a $55.00 price objective for the company. The Goldman Sachs Group upped their target price on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Scotiabank reiterated an “outperform” rating on shares of Guardant Health in a research note on Monday. Finally, Barclays raised their price objective on Guardant Health from $55.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $52.32.

Insider Transactions at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the business’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. The trade was a 4.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 107,132 shares of company stock valued at $5,249,355 in the last three months. 5.50% of the stock is currently owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.